Preferred Name |
lenalidomide |
|
Synonyms |
CC-5013 |
|
Definitions |
A thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2668" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2668" NCI Thesaurus) |
|
ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000038564 |
|
altLabel |
CC-5013 Revlimid IMiD-1 CDC 501 CC5013 |
|
Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000405858 http://purl.bioontology.org/ontology/PDQ/CDR0000393606 |
|
cui |
C1144149 C1134588 C1328651 C1135145 |
|
Date last modified |
2015-02-20 |
|
definition |
A thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2668" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2668" NCI Thesaurus) |
|
Legacy PDQ ID |
11195 |
|
LT |
TRD |
|
NCI ID |
C2668 |
|
notation |
CDR0000038564 |
|
ORIG STY |
Drug/agent |
|
prefLabel |
lenalidomide |
|
tui |
T109 T121 |